Literature DB >> 7994931

Comparison between pre- and posttreatment renal biopsies in children receiving ciclosporine for idiopathic nephrosis.

R Habib1, P Niaudet.   

Abstract

Fourty-two children with idiopathic nephrosis that had not been well controlled by other forms of therapy were treated with ciclosporine. Thirty-three of them were steroid dependent, 2 were partial steroid responders and 7 were steroid resistant. On pretreatment renal biopsy, performed in all patients less than 6 months before starting ciclosporine, minimal change disease (MCD) was diagnosed in 37 children and focal glomerular sclerosis (FGS) in 5. In order to evaluate the morphological changes of the renal parenchyma possibly induced by the drug, posttreatment biopsies were performed in these 42 patients: one in all patients after 4 to 28 months of ciclosporine, 2 in 23 patients after 18 to 42 months of treatment, 3 in 8 patients after 30 to 63 months of treatment and 4 in 2 patients who had been treated respectively for 62 and 63 months. The morphological changes on pre- and posttreatment biopsies were scored according to the severity of tubulointerstitial lesions. Grade I was considered when there were no significant changes of the renal parenchyma or when occasional scattered tubules with thickened basement membranes were present. Grade II was diagnosed when the biopsy showed several small foci of atrophic tubules with thickened basement membranes within stripes of interstitial fibrosis and grade III when confluent or extensive areas of interstitial fibrosis with atrophic and/or collapsed tubules were observed. On pretreatment renal biopsy, only one patient showed tubulointerstitial lesions (grade II). On the latest biopsy obtained, 18 patients showed grade I tubulointerstitial lesions, 15 grade II and 9 grade III. Unspecific arteriolopathy was observed in 10 patients.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7994931

Source DB:  PubMed          Journal:  Clin Nephrol        ISSN: 0301-0430            Impact factor:   0.975


  12 in total

1.  Cyclosporin A therapy for Henoch-Schönlein nephritis with nephrotic-range proteinuria.

Authors:  Jee Min Park; Sung Chul Won; Jae Il Shin; Hyunee Yim; Ki Soo Pai
Journal:  Pediatr Nephrol       Date:  2010-12-24       Impact factor: 3.714

2.  Cyclosporin therapy in patients with Alport syndrome.

Authors:  Marina Charbit; Marie-Claire Gubler; Michèle Dechaux; Marie-France Gagnadoux; Jean-Pierre Grünfeld; Patrick Niaudet
Journal:  Pediatr Nephrol       Date:  2006-09-21       Impact factor: 3.714

3.  Cyclophosphamide does not benefit patients with focal segmental glomerulosclerosis. A report of the International Study of Kidney Disease in Children.

Authors:  P Tarshish; J N Tobin; J Bernstein; C M Edelmann
Journal:  Pediatr Nephrol       Date:  1996-10       Impact factor: 3.714

4.  Cyclosporin A may cause injury to undifferentiated glomeruli persisting in patients with Alport syndrome.

Authors:  Keisuke Sugimoto; Shinsuke Fujita; Tomoki Miyazawa; Hitomi Nishi; Takuji Enya; Akane Izu; Norihisa Wada; Naoki Sakata; Mitsuru Okada; Tsukasa Takemura
Journal:  Clin Exp Nephrol       Date:  2013-07-05       Impact factor: 2.801

5.  Independent risk factors for chronic cyclosporine induced nephropathy in children with nephrotic syndrome.

Authors:  S Fujinaga; K Kaneko; T Muto; Y Ohtomo; H Murakami; Y Yamashiro
Journal:  Arch Dis Child       Date:  2006-05-02       Impact factor: 3.791

6.  Mycophenolate mofetil versus cyclosporine for remission maintenance in nephrotic syndrome.

Authors:  Eiske M Dorresteijn; Joana E Kist-van Holthe; Elena N Levtchenko; Jeroen Nauta; Wim C J Hop; Albert J van der Heijden
Journal:  Pediatr Nephrol       Date:  2008-07-12       Impact factor: 3.714

7.  Osteopontin expression and microvascular injury in cyclosporine nephrotoxicity.

Authors:  Beom Jin Lim; Pyung Kil Kim; Soon Won Hong; Hyeon Joo Jeong
Journal:  Pediatr Nephrol       Date:  2004-02-03       Impact factor: 3.714

8.  Frequently relapsing nephrotic syndrome: treatment with mycophenolate mofetil.

Authors:  Jutta Gellermann; Uwe Querfeld
Journal:  Pediatr Nephrol       Date:  2004-01       Impact factor: 3.714

9.  Expression of fibrosis-associated molecules in IgA nephropathy treated with cyclosporine.

Authors:  Beom Jin Lim; Ji Hong Kim; Soon Won Hong; Hyeon Joo Jeong
Journal:  Pediatr Nephrol       Date:  2008-12-09       Impact factor: 3.714

10.  Cyclosporine A and steroid therapy in childhood steroid-resistant nephrotic syndrome.

Authors:  Gargah Tahar; Lakhoua M Rachid
Journal:  Int J Nephrol Renovasc Dis       Date:  2010-08-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.